Eaton Scientific Retains Clinical Trial Veteran Dr. David Stark to Develop and Oversee FDA Compliant Trials of Tropine 3 for Non-Hormonal Treatment of Hot Flashes in Menopausal Women
Published: Aug 30, 2012
BEVERLY HILLS, Calif., Aug. 29, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that the Company has retained clinical trial veteran Dr. David L. Stark, D.C., Q.M.E., CCRA, to develop and oversee FDA compliant trials of Tropine 3 for non-hormonal treatment of hot flashes in menopausal women.
"The addition of Dr. Stark to the Eaton Scientific team gives a significant boost to our efforts to develop, validate, and monetize Tropine 3 as a safe and effective non-hormonal treatment of hot flashes in menopausal women," stated Michael Borkowski, CEO and President of Eaton Scientific. "We except that he will be instrumental in all aspects of our planned clinical trials going forward especially in regard to trial development, implementation, and overall FDA compliance."
Dr. Stark has over 18 years of experience from the toxicology labs to the investigator site and has been essential in all aspects clinical and device research. Dr. Stark is currently the President and CEO of Stark-SMO, a Site Management Organization whose services go far beyond that of an ordinary SMO. Through Dr. Stark's diverse and devoted networking within the industry, Stark-SMO has assembled a wide network of more than 5,000 physicians throughout the United States, which extends to the international community.
Formerly the Director of the National Institute of Clinical Research (NICR), he has been responsible for the design, organization and implementation of clinical trials for numerous pharmaceutical and device companies. Dr. Stark is one of the few individuals in the sector that has worked in the manufacturing validation of pharmaceuticals, the clinical field, and the regulatory (IRB) arenas, and therefore possesses a big-picture understanding of pharmaceutical development.
Due to his extensive and broad experiences in the inner workings of the research and regulatory aspects of clinical trials, Dr. Stark brings a unique vision to the industry and the Company as a motivated designer of superior approaches to research challenges. Most importantly, Dr. Stark is highly qualified to manage the development opportunities of the Company.
In addition to his significant accomplishments on the industry side of clinical drug and device development, Dr. Stark has experience with the FDA with a major focus on Investigational New Drugs (IND), New Drug Applications (NDA), and 510K applications. Prior to his employment at NICR, Dr. Stark was the President and Chief Executive Officer of Powder Ice, a medical products company. Additionally, Dr. Stark is a California state licensed Qualified Medical Examiner and Certified Clinical Research Associate.
About Pristine Solutions, Inc.
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women.
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Eaton Scientific Systems, Ltd.